Patents by Inventor Hing C. Wong

Hing C. Wong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190269807
    Abstract: Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.
    Type: Application
    Filed: April 29, 2019
    Publication date: September 5, 2019
    Inventors: Shari A. Price-Schiavi, Heather J. Belmont, Kimberlyn F. Card, Xiaoyun Zhu, Hing C. Wong
  • Patent number: 10358478
    Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: July 23, 2019
    Assignee: Altor Bioscience Corporation
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
  • Publication number: 20190048055
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Application
    Filed: March 27, 2018
    Publication date: February 14, 2019
    Inventors: Niraj Shrestha, Bai Liu, Peter Rhode, Hing C. Wong
  • Publication number: 20190046623
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.
    Type: Application
    Filed: March 6, 2018
    Publication date: February 14, 2019
    Inventors: Warren D. Marcus, Robert Newman, Bai Liu, Lijing You, Lin Kong, Peter Rhode, Hing C. Wong
  • Publication number: 20190022187
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Application
    Filed: March 14, 2018
    Publication date: January 24, 2019
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Publication number: 20190023766
    Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
    Type: Application
    Filed: April 11, 2018
    Publication date: January 24, 2019
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han
  • Patent number: 10150805
    Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: December 11, 2018
    Assignee: Altor Bioscience, LLC
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han
  • Publication number: 20180200366
    Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.
    Type: Application
    Filed: October 21, 2017
    Publication date: July 19, 2018
    Inventors: Hing C. Wong, Warren Marcus, Bai Liu, Wenxin Xu, Robby Newman, Karen Kage, Lijing You, Peter Rhode, Patrick Soon-Shiong
  • Publication number: 20180148493
    Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQQL).
    Type: Application
    Filed: July 25, 2017
    Publication date: May 31, 2018
    Inventors: Marilyn Fernandez, Bai Liu, Warren D. Marcus, Hing C. Wong
  • Publication number: 20180086810
    Abstract: Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and biologically active proteins and/or effector molecules. Also featured is methods of production of T cell receptor fusion and conjugate complexes as well as therapeutic compositions for use of the complexes.
    Type: Application
    Filed: May 3, 2017
    Publication date: March 29, 2018
    Inventors: Jon A. Weidanz, Kimberlyn F. Card, Hing C. Wong
  • Patent number: 9925247
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Altor Bioscience Corporation
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Publication number: 20170342119
    Abstract: The invention features soluble fusion protein complexes comprising at least two soluble fusion proteins. For example, the first fusion protein is an anti-CD3 antibody covalently linked to an interleukin-15 (IL-15) polypeptide or functional fragment thereof. The second fusion protein comprises a binding domain that recognizes disease antigens, wherein this domain is covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. One or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof, and the IL-15 domain of first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Inventors: Bai Liu, Peter Rhode, Hing C. Wong
  • Patent number: 9714279
    Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQQL).
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: July 25, 2017
    Assignee: Altor Bioscience Corporation
    Inventors: Marilyn Fernandez, Bai Liu, Warren D. Marcus, Hing C. Wong
  • Publication number: 20170088597
    Abstract: The invention features therapies using an IL-15-based superagonist complex to effectively treat subjects with cancer.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 30, 2017
    Inventors: Hing C. Wong, Emily K. Jeng, S. Onder Alpdogan
  • Patent number: 9593152
    Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: March 14, 2017
    Assignee: Altor Bioscience Corporation
    Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
  • Publication number: 20160367635
    Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
    Type: Application
    Filed: September 1, 2016
    Publication date: December 22, 2016
    Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
  • Publication number: 20160355567
    Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.
    Type: Application
    Filed: July 19, 2016
    Publication date: December 8, 2016
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
  • Patent number: 9464127
    Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: October 11, 2016
    Assignee: Altor Bioscience Corporation
    Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
  • Patent number: 9428573
    Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: August 30, 2016
    Assignee: Altor Bioscience Corporation
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
  • Publication number: 20160213750
    Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
    Type: Application
    Filed: March 29, 2016
    Publication date: July 28, 2016
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han